| |
Original Artikel |
Datum |
Titel |
Autoren Alle Autoren |
| 1 |
[GO] |
2023―Dez―01 |
Latest development of approved COVID-19 drugs and COVID-19 drugs undergoing late stage clinical trials |
Bingru Feng, Kai Fu |
| 2 |
[GO] |
2023―Jul―25 |
The importance of good practices and false hits for QSAR-driven virtual screening real application: a SARS-CoV-2 main protease (Mpro) case study |
Mateus Sá Magalhães Serafim, Simone Queiroz Pantaleão, Elany Barbosa da Silva, James H. McKerrow, Anthony J. O’Donoghue, Bruno Eduardo Fernandes Mota, et al. (+2) Kathia Maria Honorio, Vinícius Gonçalves Maltarollo |
| 3 |
[GO] |
2023―Jun―01 |
Lessons that can be learned from the SARS-CoV-2 pandemic and their impact on the prophylaxis and treatment development for neglected tropical arboviruses |
Danilo Rosa-Nunes, Danilo B. M. Lucchi, Robert Andreata-Santos, Luiz Mario R. Janini, Carla Torres Braconi |
| 4 |
[GO] |
2023―Feb―27 |
Editorial: Development/repurposing of drugs to tackle the multiple variants of SARS-CoV-2 |
Dinorah Gambino |
| 5 |
[GO] |
2023―Jan―24 |
The Need for Speed and Efficiency: A Brief Review of Small Molecule Antivirals for COVID-19 |
Ana C. Puhl, Thomas R. Lane, Fabio Urbina, Sean Ekins |
| 6 |
[GO] |
2023―Jan―24 |
COVID-19 Therapies: Protease Inhibitions and Novel Degrader Strategies |
Michèle Reboud-Ravaux, Chahrazade El Amri |
| 7 |
[GO] |
2023―Jan―05 |
Drug repurposing screening validated by experimental assays identifies two clinical drugs targeting SARS-CoV-2 main protease |
Denis N. Prada Gori, Santiago Ruatta, Martín Fló, Lucas N. Alberca, Carolina L. Bellera, Soonju Park, et al. (+7) Jinyeong Heo, Honggun Lee, Kyu-Ho Paul Park, Otto Pritsch, David Shum, Marcelo A. Comini, Alan Talevi |
| 8 |
[GO] |
2022―Sep―08 |
Editorial: Development of COVID-19 therapies: Lessons learnt and ongoing efforts |
Bruno O. Villoutreix, Claudio N. Cavasotto, Juan Fernandez-Recio |
| 9 |
[GO] |
2022―Aug―31 |
Bismuth subsalicylate as potential treatment for Covid-19 pneumonia: A case series report |
Chris Kahlenborn, Walter B. Severs, Khalid Nawab |
| 10 |
[GO] |
2022―Aug―26 |
The challenges and opportunities for the development of COVID-19 therapeutics and preparing for the next pandemic |
Emmanuel O Ogbadoyi, Ndagi Umar |
| 11 |
[GO] |
2022―Jul―18 |
Nanobodies: COVID-19 and Future Perspectives |
Guillermo Valenzuela-Nieto, Zaray Miranda-Chacon, Constanza Salinas-Rebolledo, Ronald Jara, Alexei Cuevas, Anne Berking, Alejandro Rojas-Fernandez |
| 12 |
[GO] |
2022―Mai―26 |
Overcoming Market Failures in Pandemic Drug Discovery Through Open Science: A Canadian Solution |
E. Richard Gold, Aled M. Edwards |
| 13 |
[GO] |
2022―Mai―10 |
Furin and COVID-19: Structure, Function and Chemoinformatic Analysis of Representative Active Site Inhibitors |
Bruno O. Villoutreix, Iker Badiola, Abdel-Majid Khatib |
| 14 |
[GO] |
2022―Mai―10 |
Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective |
G. Moroy, P. Tuffery |
| 15 |
[GO] |
2022―Mai―02 |
Advances in Modelling COVID-19 in Animals |
Petr Nickl, Miles Joseph Raishbrook, Linn Amanda Syding, Radislav Sedlacek |
| 16 |
[GO] |
2022―Apr―25 |
Developing Small-Molecule Inhibitors of Protein-Protein Interactions Involved in Viral Entry as Potential Antivirals for COVID-19 |
Peter Buchwald |
| 17 |
[GO] |
2022―Mrz―28 |
Review of Clinical Trials of COVID-19 Vaccination Booster in SARS-CoV-2 Variants Era: To Take It or Not To Take It |
Michael Zhipeng Yan, Ming Yang, Ching-Lung Lai |
| 18 |
[GO] |
2022―Jan―25 |
Is Covid-19 Severity Associated With ACE2 Degradation? |
Ugo Bastolla, Patrick Chambers, David Abia, Maria-Laura Garcia-Bermejo, Manuel Fresno |
